[Treatment of gouty purine metabolism disorder with mercapto-pyrazolo-pyrimidine (thiopurinol)].
D000493:Allopurinol / Q000378:metabolism; D002137:Calculi / Q000188:drug therapy; D004361:Drug Tolerance; D005260:Female; D006073:Gout / Q000188:drug therapy*; D006150:Guanine Nucleotides / Q000096:biosynthesis; D006801:Humans; D008297:Male; D011686:Purine-Pyrimidine Metabolism, Inborn Errors / Q000188:drug therapy*; D011687:Purines / Q000037:antagonists & inhibitors / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use*; D014166:Transferases / Q000378:metabolism; D014527:Uric Acid / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism; D014528:Uricosuric Agents / Q000627:therapeutic use; D014969:Xanthine Oxidase / Q000378:metabolism; D014970:Xanthines / Q000097:blood / Q000652:urine
D006150:Guanine Nucleotides; D011687:Purines; D011743:Pyrimidines; D014528:Uricosuric Agents; D014970:Xanthines; D014527:Uric Acid; D000493:Allopurinol; D014969:Xanthine Oxidase; D014166:Transferases
Le traitement de la dyspurinie goutteuse par la mercapto-pyrazolol-pyrimidine (MPP: thiopurinol)